natgillin/translations-raw huggingface dataset:
The patient should take two 10 mg film-coated tablets (20 mg) or one 20 mg film-coated tablet per day. 
Bolesnik treba uzimati dvije filmom obložene tablete od 10 mg (20 mg) ili jednu filmom obloženu tabletu od 20 mg dnevno.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine. 
Ako ste nedavno promijenili ili namjeravate značajno promijeniti svoj način prehrane (npr. s normalne prehrane na strogu vegetarijansku prehranu) ili ako bolujete od stanja renalne tubularne acidoze (RTA - izrazito povećana količina tvari koje tvore kiseline u krvi zbog poremećaja rada bubrega (slaba funkcija bubrega)) ili teških infekcija mokraćnog trakta (struktura kroz koje prolazi mokraća), trebali bi obavijestiti svog liječnika, jer će Vam liječnik možda morati prilagoditi dozu lijeka.
What Marixino contains - The active substance is memantine hydrochloride. 
Što Marixino sadrži - Djelatna tvar je memantinklorid.
In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m2 and part of total renal clearance is achieved by tubular secretion. 
Kod dobrovoljaca s normalnom funkcijom bubrega, ukupni klirens (Cltot) iznosi do 170 ml/min/1,73 m², te se dio ukupnog bubrežnog klirensa postiže tubularnom sekrecijom.
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p = 0.003) and CIBIC-plus (p = 0.004) at week 24 (last observation carried forward (LOCF)). 
Bolesnici liječeni memantinom pokazali su statistički značajno bolji učinak nego bolesnici koji su primali placebo u pogledu primarnih ishoda: skala procjene Alzheimerove bolesti (ADAS-cog) (p=0,003) i CIBIC-plus (p=0,004) u 24. tjednu liječenja (zadnje opažanje preneseno nadalje (LOCF)).
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed. 
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar između memantina i gliburida/metformina ili donepezila.
This is increased to one tablet once a day (1 x 10 mg) in the second week and to 1 and a half tablets once a day (1 x 15 mg) in the third week. 
Ova doza se povećava na jednu tabletu jedanput na dan (1 x 10 mg) u drugom tjednu, te na jednu i pol tabletu jednom dnevno (1 x 15 mg) u trećem tjednu.
In these situations the treatment should be carefully supervised, and the clinical benefit of Marixino reassessed by your doctor on a regular basis. 
U tim slučajevima liječenje mora biti pažljivo nadzirano, a Vaš liječnik treba redovito ponovno procjenjivati kliničku korist od uzimanja lijeka Marixino.
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 60 film-coated tablets 70 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets 
14 filmom obloženih tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 42 filmom obložene tablete 50 filmom obloženih tableta 56 filmom obloženih tableta 60 filmom obloženih tableta 70 filmom obloženih tableta 84 filmom obloženih tableta 90 filmom obloženih tableta 98 filmom obloženih tableta 100 filmom obloženih tableta 112 filmom obloženih tableta
Nervous System disorders 
Poremećaji živčanog sustava
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002). 
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus): p=0,025; kooperativno ispitivanje Alzheimerove bolesti - aktivnosti svakodnevnog života (ADCS-ADLsev): p=0,003; skup znakova teške onesposobljenosti (SIB): p=0,002).
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme: 
Kako bi se smanjio rizik od nuspojava, ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog liječenja:
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21 % vs. 11 %, p < 0.0001). 
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja, rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p<0,0001).
Not known (frequency cannot be estimated from the available data): - Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions 
Nepoznate učestalosti (učestalost se ne može procijeniti iz raspoloživih podataka): - Upala gušterače, upala jetre (hepatitis) i psihotične reakcije.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme. 
Kako bi se smanjio rizik od nuspojava, ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog liječenja.
Women taking memantine should not breast-feed. 
Žene koje uzimaju memantin ne smiju dojiti.
No data on the use of memantine in patients with severe hepatic impairment are available. 
Nisu dostupni podaci o primjeni memantina kod bolesnika s teškim oštećenjem jetre.
How to store Marixino 
Kako čuvati Marixino
At the beginning of treatment you will start by using half a 10 mg tablet once a day (1 x 5 mg). 
Liječenje ćete započeti korištenjem polovice tablete od 10 mg jedanput na dan (1 x 5 mg).
Standard clinical procedures to remove active substance material, e.g. gastric lavage, carbo medicinalis (interruption of potential entero-hepatic recirculation), acidification of urine, forced diuresis should be used as appropriate. 
Treba koristiti standardne kliničke postupke za uklanjanje djelatne tvari, npr. ispiranje želuca, primjenu medicinskog ugljena (prekidanje potencijalne enterohepatičke recirkulacije), zakiseljavanje urina te forsiranu diurezu, kako je prikladno.
Dosage in patients with impaired kidney function If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. 
Ako imate oštećenu funkciju bubrega, liječnik će odlučiti o dozi koja odgovara Vašem stanju.
The recommended dose of Marixino for adults and older people is 20 mg once a day. 
Preporučena doza lijeka Marixino za odrasle i starije osobe je 20 mg jednom dnevno.
In man, about 80 % of the circulating memantine-related material is present as the parent compound. 
Kod ljudi je oko 80% memantina u cirkulaciji prisutno u nepromijenjenom obliku.
Pregnancy The use of memantine in pregnant women is not recommended. 
Trudnicama se ne preporučuje upotreba memantina.
In patients with severe renal impairment (creatinine clearance 5 - 29 ml/min) daily dose should be 10 mg per day. 
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5 - 29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
In patients with mildly impaired renal function (creatinine clearance 50 - 80 ml/min) no dose adjustment is required. 
Kod bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina 50 - 80 ml/min) nije potrebna prilagodba doze.
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg per day. 
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30 - 49 ml/min), dnevna doza bi trebala biti 10 mg na dan.
If you take more Marixino than you should - In general, taking too much Marixino should not result in any harm to you. 
- Općenito, uzimanje previše lijeka Marixino ne bi Vam trebalo naškoditi.
There are no or limited amount of data from the use of memantine in pregnant women. 
Nema podataka ili su podaci o primjeni memantina u trudnica ograničeni.
Dosage The recommended dose of Marixino for adults and older people is 20 mg once a day. 
Doziranje Preporučena doza lijeka Marixino za odrasle i starije osobe je 20 mg jednom dnevno.
Only limited experience with overdose is available from clinical studies and post-marketing experience. 
Iz kliničkih ispitivanja i nakon stavljanja lijeka u promet dostupno je samo ograničeno iskustvo u vezi s predoziranjem.
Very rare 
Vrlo rijetko napadaji
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11 - 23) were randomised. 
U drugom monoterapijskom ispitivanju blage do umjerene Alzheimerove bolesti randomizirano je ukupno 470 bolesnika (početne vrijednosti ukupnog MMSE od 11-23).
Psychotic reactions 
Nepoznato psihotične reakcije
Marixino 10 mg film-coated tablets Each film-coated tablet contains 51.45 mg lactose monohydrate. 
Marixino 10 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 51,45 mg laktoze hidrata.
Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine. 
Svaka filmom obložena tableta sadrži 10 mg memantinklorida, što odgovara 8,31 mg memantina.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Unutar pojedine skupine učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
• Periodic Safety Update Reports 
• Periodička izvješća o neškodljivosti lijeka
The usual starting dose is half a tablet once a day (1 x 5 mg) for the first week. 
Uobičajena početna doza iznosi pola tablete jedanput na dan (1 x 5 mg) tijekom prvog tjedna.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients. 
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
Marixino 20 mg film-coated tablets Each film-coated tablet contains 102.90 mg lactose monohydrate. 
Marixino 20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 102,90 mg laktoze hidrata.
The following Adverse Reactions listed in the table below have been accumulated in clinical studies with memantine and since its introduction in the market. 
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s memantinom i nakon stavljanja lijeka u promet su prikazane u tablici ispod.
Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. 
Memantin je nekompetitivni antagonist NMDA-receptora, umjerenog afiniteta i ovisan o naponu.
Marixino contains the active substance memantine hydrochloride. 
Marixino sadrži djelatnu tvar memantinklorid.
Administration of Marixino is not recommended in patients with severe hepatic impairment. 
Ne preporučuje se primjena lijeka Marixino kod bolesnika s teškim oštećenjem jetre.
Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine. 
Svaka filmom obložena tableta sadržava 20 mg memantinklorida što odgovara 16,62 mg memantina.
Week 3 (day 15-21) The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days. 
3. tjedan (15-21. dan) Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
Tablet core: lactose monohydrate, microcrystalline cellulose (E460), anhydrous colloidal silica, talc (E553b), magnesium stearate (E470b). 
Jezgra tablete: laktoza hidrat, mikrokristalična celuloza (E460), koloidni bezvodni silicijev dioksid, talk (E553b), magnezijev stearat (E470b).
Film coating: methacrylic acid-ethyl acrylate copolymer (1:1), sodium laurilsulfate, polysorbate 80, talc (E553b), triacetin, simeticone. 
Film ovojnica: metakrilatna kiselina/etilakrilat kopolimer (1:1), natrijev laurilsulfat, polisorbat 80, talk (E553b), triacetin, simetikon.
Week 2 (day 8-14) The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days. 
2. tjedan (8-14. dan) Bolesnik treba uzimati jednu filmom obloženu tabletu od 10 mg (10 mg) dnevno tijekom 7 dana.
Uncommon (may affect up to 1 in 100 people): - Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism). 
Manje česte (mogu se javiti u manje od 1 na 100 osoba): - Umor, gljivične infekcije, smetenost, halucinacije, povraćanje, poremećaj hoda, zatajenje srca i zgrušavanje venske krvi (tromboza/tromboembolija).
Week 1 (day 1-7) The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days. 
1. tjedan (1-7. dan) Bolesnik treba uzimati polovicu filmom obložene tablete od 10 mg (5 mg) dnevno tijekom 7 dana.
In post-marketing experience these reactions have been reported in patients treated with memantine. 
Ove su nuspojave prijavljene nakon stavljanja lijeka u promet kod bolesnika liječenih memantinom.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT. 
- Pri istodobnoj primjeni memantina i hidroklorotiazida (HCT-a) ili bilo koje od kombinacija s HCT-om, postoji mogućnost smanjenja koncentracije HCT-a u serumu.
Two 10 mg tablets 
Dvije tablete od 10 mg
One and a half 10 mg tablets 
Jedna i pol tableta od 10 mg
Gait abnormal 
Manje često abnormalni hod
White, oval, biconvex film-coated tablet, scored on one side (tablet length: 12.2-12.9 mm, thickness: 3.5-4.5 mm). 
Bijela, ovalna, bikonveksna filmom obložena tableta, s razdjelnom crtom na jednoj strani (dužina tablete: 12,2-12,9 mm, debljina: 3,5-4,5 mm).
One 10 mg tablet 
Jedna tableta od 10 mg
Lactose monohydrate Cellulose, microcrystalline (E460) Silica, colloidal anhydrous Talc (E553b) 
Jezgra tablete laktoza hidrat celuloza, mikrokristalična (E460) silicijev dioksid, koloidni, bezvodni talk (E553b) magnezijev stearat (E470b)
Marixino 10 mg film-coated tablets Marixino 20 mg film-coated tablets 
Marixino 10 mg filmom obložene tablete Marixino 20 mg filmom obložene tablete
Common (may affect up to 1 in 10 people): - Headache, sleepiness, constipation, elevated liver function test, dizziness, balance disorders, 
Česte (mogu se javiti u manje od 1 na 10 osoba): - Glavobolja, pospanost, zatvor, povišeni rezultati testova jetrene funkcije, omaglica, poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.
Film coating: methacrylic acid-ethyl acrylate copolymer (1:1),sodium laurilsulfate, polysorbate 80, talc (E553b), triacetin, simeticone. 
Film ovojnica metakrilatna kiselina/etilakrilat kopolimer (1:1) natrijev laurilsulfat polisorbat 80 talk (E553b) triacetin simetikon
Marixino 10 mg film-coated tablets 
Marixino 10 mg filmom obložene tablete
Marixino 20 mg film-coated tablets 
Marixino 20 mg filmom obložene tablete
What Marixino looks like and contents of the pack White, oval, biconvex film-coated tablets, scored on one side (tablet length: 12.2-12.9 mm, thickness: 3.5-4.5 mm). 
Bijele, ovalne, bikonveksne filmom obložene tablete s razdjelnom crtom na jednoj strani (dužina tablete: 12,2-12,9 mm, debljina: 3,5-4,5 mm).
Marixino 20 mg film-coated tablets memantine hydrochloride 
Marixino 20 mg filmom obložene tablete memantinklorid
Marixino 10 mg film-coated tablets memantine hydrochloride 
Marixino 10 mg filmom obložene tablete memantinklorid
White, oval, biconvex film-coated tablet (tablet length: 15.7-16.4 mm, thickness: 4.7-5.7 mm). 
Bijela, ovalna, bikonveksna filmom obložena tableta (dužina tablete: 15,7-16,4 mm, debljina: 4,7-5,7 mm).
Half a 10 mg tablet 
Pola tablete od 10 mg
14 film-coated tablets: EU/1/13/820/001 28 film-coated tablets: EU/1/13/820/002 30 film-coated tablets: EU/1/13/820/003 42 film-coated tablets: EU/1/13/820/004 50 film-coated tablets: EU/1/13/820/005 56 film-coated tablets: EU/1/13/820/006 60 film-coated tablets: EU/1/13/820/007 70 film-coated tablets: EU/1/13/820/008 84 film-coated tablets: EU/1/13/820/009 90 film-coated tablets: EU/1/13/820/010 98 film-coated tablets: EU/1/13/820/011 100 film-coated tablets: EU/1/13/820/012 112 film-coated tablets: EU/1/13/820/013 
14 filmom obloženih tableta: EU/1/13/820/001 28 filmom obloženih tableta: EU/1/13/820/002 30 filmom obloženih tableta: EU/1/13/820/003 42 filmom obložene tablete: EU/1/13/820/004 50 filmom obloženih tableta: EU/1/13/820/005 56 filmom obloženih tableta: EU/1/13/820/006 60 filmom obloženih tableta: EU/1/13/820/007 70 filmom obloženih tableta: EU/1/13/820/008 84 filmom obložene tablete: EU/1/13/820/009 90 filmom obloženih tableta: EU/1/13/820/010 98 filmom obloženih tableta: EU/1/13/820/011 100 filmom obloženih tableta: EU/1/13/820/012 112 filmom obloženih tableta: EU/1/13/820/013
14 film-coated tablets: EU/1/13/820/014 28 film-coated tablets: EU/1/13/820/015 30 film-coated tablets: EU/1/13/820/016 42 film-coated tablets: EU/1/13/820/017 50 film-coated tablets: EU/1/13/820/018 56 film-coated tablets: EU/1/13/820/019 60 film-coated tablets: EU/1/13/820/020 70 film-coated tablets: EU/1/13/820/021 84 film-coated tablets: EU/1/13/820/022 90 film-coated tablets: EU/1/13/820/023 98 film-coated tablets: EU/1/13/820/024 100 film-coated tablets: EU/1/13/820/025 112 film-coated tablets: EU/1/13/820/026 
14 filmom obloženih tableta: EU/1/13/820/014 28 filmom obloženih tableta: EU/1/13/820/015 30 filmom obloženih tableta: EU/1/13/820/016 42 filmom obložene tablete: EU/1/13/820/017 50 filmom obloženih tableta: EU/1/13/820/018 56 filmom obloženih tableta: EU/1/13/820/019 60 filmom obloženih tableta: EU/1/13/820/020 70 filmom obloženih tableta: EU/1/13/820/021 84 filmom obložene tablete: EU/1/13/820/022 90 filmom obloženih tableta: EU/1/13/820/023 98 filmom obloženih tableta: EU/1/13/820/024 100 filmom obloženih tableta: EU/1/13/820/025 112 filmom obloženih tableta: EU/1/13/820/026
EU/1/13/820/014 14 film-coated tablets EU/1/13/820/015 28 film-coated tablets EU/1/13/820/016 30 film-coated tablets EU/1/13/820/017 42 film-coated tablets EU/1/13/820/018 50 film-coated tablets EU/1/13/820/019 56 film-coated tablets EU/1/13/820/020 60 film-coated tablets EU/1/13/820/021 70 film-coated tablets EU/1/13/820/022 84 film-coated tablets EU/1/13/820/023 90 film-coated tablets EU/1/13/820/024 98 film-coated tablets EU/1/13/820/025 100 film-coated tablets EU/1/13/820/026 112 film-coated tablets 
EU/1/13/820/014: 14 filmom obloženih tableta EU/1/13/820/015: 28 filmom obloženih tableta EU/1/13/820/016: 30 filmom obloženih tableta EU/1/13/820/017: 42 filmom obložene tablete EU/1/13/820/018: 50 filmom obloženih tableta EU/1/13/820/019: 56 filmom obloženih tableta EU/1/13/820/020: 60 filmom obloženih tableta EU/1/13/820/021: 70 filmom obloženih tableta EU/1/13/820/022: 84 filmom obložene tablete EU/1/13/820/023: 90 filmom obloženih tableta EU/1/13/820/024: 98 filmom obloženih tableta EU/1/13/820/025: 100 filmom obloženih tableta EU/1/13/820/026: 112 filmom obloženih tableta
EU/1/13/820/001 14 film-coated tablets EU/1/13/820/002 28 film-coated tablets EU/1/13/820/003 30 film-coated tablets EU/1/13/820/004 42 film-coated tablets EU/1/13/820/005 50 film-coated tablets EU/1/13/820/006 56 film-coated tablets EU/1/13/820/007 60 film-coated tablets EU/1/13/820/008 70 film-coated tablets EU/1/13/820/009 84 film-coated tablets EU/1/13/820/010 90 film-coated tablets EU/1/13/820/011 98 film-coated tablets EU/1/13/820/012 100 film-coated tablets EU/1/13/820/013 112 film-coated tablets 
EU/1/13/820/001: 14 filmom obloženih tableta EU/1/13/820/002: 28 filmom obloženih tableta EU/1/13/820/003: 30 filmom obloženih tableta EU/1/13/820/004: 42 filmom obložene tablete EU/1/13/820/005: 50 filmom obloženih tableta EU/1/13/820/006: 56 filmom obloženih tableta EU/1/13/820/007: 60 filmom obloženih tableta EU/1/13/820/008: 70 filmom obloženih tableta EU/1/13/820/009: 84 filmom obložene tablete EU/1/13/820/010: 90 filmom obloženih tableta EU/1/13/820/011: 98 filmom obloženih tableta EU/1/13/820/012: 100 filmom obloženih tableta EU/1/13/820/013: 112 filmom obloženih tableta
Balance disorders 
Često poremećaji ravnoteže
Do not give this medicine to children or adolescents under 18 years of age. 
Nemojte davati ovaj lijek djeci ili adolescentima mlađim od 18 godina.
For external use only. 
Samo za vanjsku uporabu.
• Ringing in the ears 
• zvonjenje u ušima
• a high temperature 
• visoka temperatura
The expiry date refers to the last day of that month. 
Rok valjanosti se odnosi na zadnji dan navedenog mjeseca.
These effects may be life-threatening. 
Takvi učinci mogu biti opasni po život.
Partners completed the PEP questionnaire at month three. 
Partneri su popunjavali PEP upitnik u trećem mjesecu.
This is more likely when certain medicines have been taken at the same time. 
To je vjerojatnije kad se istovremeno koriste još neki lijekovi.
If this happens, the skin becomes bluish-grey due to a lack of oxygen. 
Dogodi li se to, koža postane plavičasto-siva uslijed pomanjkanja kisika.
What Fortacin is and what it is used for 
Što je Fortacin i za što se koristi
After first use: 12 weeks 
Nakon prvog otvaranja: 12 tjedana
Check the material that your contraceptive or your partner's contraceptive is made of. 
Provjerite od kojeg su materijala izrađena kontracepcijska sredstva vas ili partnerice.
If you do apply too much, wipe it off. 
Nanesete li previše, obrišite.
Store below 25°C. 
Čuvati ispod 25 °C.
Patients should be advised to use alternative methods of contraception. 
Bolesnicima treba savjetovati korištenje drugih metoda kontracepcije.
The metal container is pressurised. 
Metalni spremnik je pod pritiskom.
• Inability to develop or maintain an erection 
• nemogućnost postizanja ili održavanja erekcije
Note, this dose did result in tumours. 
Napomena, ta doza je rezultirala tumorima.
• other local anaesthetics 
• druge lokalne anestetike
Date of first authorisation: 15 November 2013 Date of latest renewal: 17 September 2018 
Datum posljednje obnove odobrenja: 17. rujna 2018.
Pharmaserve (North West) Ltd 9 Arkwright Road Astmoor Industrial Estate Runcorn WA7 1NU United Kingdom 
Pharmaserve (North West) Ltd 9 Arkwright Road Astmoor Industrial Estate Runcorn WA7 1NU Ujedinjeno Kraljevstvo
These belong to a group of medicines called local anaesthetics. 
Oni pripadaju skupini lijekova pod nazivom lokalni anestetici.
If you use more Fortacin than you should 
Ako primijenite više lijeka Fortacin nego što ste trebali
Contents of the pack and other information What Fortacin contains 
Sadržaj pakiranja i druge informacije Što Fortacin sadrži
This hypoaesthesia may mask normal pain sensations and, therefore, increase the dangers of localised injury. 
Takva hipoestezija može prikrivati normalne osjete boli i posljedično povećati opasnost od lokalnih ozljeda.
Other medicines and Fortacin 
Drugi lijekovi i Fortacin
There is limited data on the efficacy and safety of Fortacin in patients 65 years and over. 
Podaci o djelotvornosti i sigurnosti lijeka Fortacin u pacijenata u dobi od 65 godina i više su ograničeni.
Also contains: norflurane 
Također sadržava: norfluran
However, there may be some exposure in female partners of men treated with Fortacin. 
Međutim, može doći do određene izloženosti kod partnerica muškaraca kod kojih je primijenjen Fortacin.
Genotoxicity and carcinogenicity 
Genotoksičnost i karcinogenost